PL378432A1 - Inhibitory p38 i sposoby ich zastosowania - Google Patents

Inhibitory p38 i sposoby ich zastosowania

Info

Publication number
PL378432A1
PL378432A1 PL378432A PL37843204A PL378432A1 PL 378432 A1 PL378432 A1 PL 378432A1 PL 378432 A PL378432 A PL 378432A PL 37843204 A PL37843204 A PL 37843204A PL 378432 A1 PL378432 A1 PL 378432A1
Authority
PL
Poland
Prior art keywords
inhibitors
methods
Prior art date
Application number
PL378432A
Other languages
English (en)
Other versions
PL214032B1 (pl
Inventor
Mark Munson
David A. Mareska
Youngboo Kim
Robert Groneberg
James Rizzi
Martha Rodriguez
Ganghyeok Kim
Guy Vigers
Chang Rao
Devan Balachari
Darren Harvey
Original Assignee
Array Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/378,164 external-priority patent/US7135575B2/en
Application filed by Array Biopharma, Inc. filed Critical Array Biopharma, Inc.
Publication of PL378432A1 publication Critical patent/PL378432A1/pl
Publication of PL214032B1 publication Critical patent/PL214032B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
PL378432A 2003-03-03 2004-02-25 Zwiazki bedace inhibitorami kinazy p38, kompozycja farmaceutyczna je zawierajaca oraz ich zastosowanie do wytwarzania leku do leczenia stanu, w którym posredniczy kinaza p38 PL214032B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/378,164 US7135575B2 (en) 2003-03-03 2003-03-03 P38 inhibitors and methods of use thereof
US10/688,849 US20040180896A1 (en) 2003-03-03 2003-10-15 P38 inhibitors and methods of use thereof

Publications (2)

Publication Number Publication Date
PL378432A1 true PL378432A1 (pl) 2006-04-03
PL214032B1 PL214032B1 (pl) 2013-06-28

Family

ID=32965317

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378432A PL214032B1 (pl) 2003-03-03 2004-02-25 Zwiazki bedace inhibitorami kinazy p38, kompozycja farmaceutyczna je zawierajaca oraz ich zastosowanie do wytwarzania leku do leczenia stanu, w którym posredniczy kinaza p38

Country Status (12)

Country Link
US (1) US7521447B2 (pl)
EP (1) EP1606283B1 (pl)
JP (1) JP4617299B2 (pl)
KR (1) KR101099281B1 (pl)
AU (1) AU2004218463B2 (pl)
CA (1) CA2517517C (pl)
IS (1) IS2675B (pl)
MX (1) MXPA05009459A (pl)
NO (1) NO328913B1 (pl)
PL (1) PL214032B1 (pl)
RU (1) RU2357957C2 (pl)
WO (1) WO2004078116A2 (pl)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL374758A1 (pl) * 2002-10-24 2005-10-31 Merck Patent Gmbh Pochodne metylenomocznika
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP4895811B2 (ja) * 2003-09-11 2012-03-14 ケミア，インコーポレイテッド サイトカイン阻害剤
KR101223914B1 (ko) 2003-11-21 2013-01-18 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제
MXPA06009462A (es) 2004-02-27 2007-03-15 Hoffmann La Roche Derivados pirazolo heteroaril fusionados.
AU2005273612B2 (en) 2004-08-12 2010-10-14 Pfizer Inc. Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
EP1647549A1 (en) * 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
CN101052633A (zh) * 2004-11-02 2007-10-10 辉瑞大药厂 制备吲唑化合物的方法
EP1809621A1 (en) * 2004-11-02 2007-07-25 Pfizer, Inc. Methods of preparing indazole compounds
CN101044138A (zh) * 2004-11-02 2007-09-26 辉瑞有限公司 吲唑化合物的制备方法
UA95907C2 (en) * 2005-05-02 2011-09-26 Эррей Биофарма Инк. Mitotic kinesin inhibitors and methods of use thereof
EP1883404A4 (en) * 2005-05-11 2010-03-31 Array Biopharma Inc P38 INHIBITORS AND METHODS OF USE
BRPI0615270A2 (pt) * 2005-08-25 2009-08-04 Hoffmann La Roche pirazol fundido como inibidores de p38 map cinase
AU2006283941A1 (en) 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag P38 MAP kinase inhibitors and methods for using the same
WO2007023110A2 (en) 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag P38 map kinase inhibitors and methods for using the same
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US20100022571A1 (en) * 2005-09-16 2010-01-28 Palle Venkata P Substituted pyrazolo [3,4-b]pyridines as phosphodiesterase inhibitors
EA019983B1 (ru) * 2005-10-07 2014-07-30 Экселиксис, Инк. Ингибиторы mek и способы их применения
WO2007047397A2 (en) * 2005-10-13 2007-04-26 Smithkline Beecham Corporation Phenol ethers as modulators of the opioid receptors
EP2514751A1 (en) * 2005-11-15 2012-10-24 Vertex Pharmaceuticals, Inc. Azaindazoles useful as inhibitor of kinases
JPWO2007063868A1 (ja) * 2005-11-29 2009-05-07 東レ株式会社 アリールメチレンウレア誘導体及びその用途
JP5131990B2 (ja) * 2006-01-31 2013-01-30 アレイ バイオファーマ、インコーポレイテッド キナーゼ阻害剤およびその使用方法
CA2647949A1 (en) * 2006-03-29 2007-11-08 Array Biopharma Inc. P38 inhibitors and methods of use thereof
DK2068886T3 (da) * 2006-10-03 2013-11-18 Tekmira Pharmaceuticals Corp Lipidholdige præparater
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
CA2671982C (en) * 2006-12-14 2016-01-26 Exelixis, Inc. Methods of using mek inhibitors
WO2008076446A1 (en) * 2006-12-18 2008-06-26 Coleman Peter R Accelerated opiate dependence detoxification process
CN101558072A (zh) * 2006-12-19 2009-10-14 霍夫曼-拉罗奇有限公司 吡唑并[3,4-d]嘧啶p38map激酶抑制剂
CA2673095C (en) * 2006-12-20 2016-03-15 Nerviano Medical Sciences S.R.L. Indazole derivatives as kinase inhibitors for the treatment of cancer
WO2008104473A2 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Pyrazolopyriidine derivatives and their use as kinase inhibitors
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
US8202899B2 (en) * 2007-07-25 2012-06-19 Array Biopharma Inc. Pyrazole urea derivatives used as kinase inhibitors
EP2070929A1 (en) 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
JP2011528005A (ja) * 2008-07-15 2011-11-10 エフ．ホフマン−ラ ロシュ アーゲー 置換インドリル及びインダゾリル誘導体及びそれらの使用
MX2011003553A (es) 2008-10-02 2011-05-25 Respivert Ltd Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38.
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
MX2011006219A (es) * 2008-12-11 2011-06-28 Respivert Ltd Inhibidores de la proteina cinasa activada por el mitogeno p38.
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
BR112012008483A2 (pt) * 2009-10-12 2019-09-24 Hoffmann La Roche combunações de um inibidor de pi3k e um inibidor de mex
MX2012009377A (es) 2010-02-11 2012-09-12 Univ Vanderbilt Benzotiazoles y azabenzotiazoles como potenciadores alostericos mglur4, composiciones y metodos para tratar la disfuncion neurologica.
RU2013142648A (ru) 2011-03-16 2015-04-27 Ф. Хоффманн-Ля Рош Аг 6,5-гетероцикл пропаргиловые спирты и их применения
SG10201604656YA (en) * 2011-12-09 2016-07-28 Chiesi Farma Spa Kinase inhibitors
CN104245677B (zh) * 2012-03-01 2017-05-10 阵列生物制药公司 1‑(3‑叔丁基‑1‑对甲苯基‑1h‑吡唑‑5‑基)‑3‑(5‑氟‑2‑(1‑(2‑羟乙基)‑1h‑吲唑‑5‑基氧基)苯甲基)脲盐酸盐的晶形
JP2015530378A (ja) * 2012-08-29 2015-10-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 変形性関節症の処置のためのｄｄｒ２インヒビター
SI2909188T1 (en) 2012-10-12 2018-07-31 Exelixis, Inc. A novel process for the manufacture of compounds for use in the treatment of cancer
JP6433922B2 (ja) 2013-02-27 2018-12-05 アレイ バイオファーマ、インコーポレイテッド インダゾール誘導体の調製に使用するための中間体およびその調製方法
WO2014145485A2 (en) 2013-03-15 2014-09-18 The Trustees Of Columbia University In The City Of New York Map kinase modulators and uses thereof
EP3057934B1 (en) * 2013-10-18 2019-03-27 Blanchette Rockefeller Neurosciences, Institute Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases
CN104974160B (zh) * 2014-04-08 2017-12-05 辰欣药业股份有限公司 2‑甲基吡唑并[1,5‑a]嘧啶‑6‑羧酸衍生物及其应用
EP3233797B1 (en) * 2015-01-18 2019-05-08 SRI International Inc. Map4k4 (hgk) inhibitors
RU2675496C1 (ru) * 2017-03-31 2018-12-20 Федеральное государственное бюджетное учреждение науки Институт нефтехимии и катализа Российской академии наук Способ получения алкиловых эфиров гидроксибензойных кислот
CN108947879B (zh) * 2017-05-17 2022-06-28 中国科学院上海药物研究所 Prmt i型抑制剂及其制备方法和用途
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
LT3691620T (lt) 2017-10-05 2022-09-26 Fulcrum Therapeutics, Inc. P38 kinazės inhibitoriai, sumažinantys dux4 ir pasrovinių genų raišką, skirti fshd gydymui
US10889548B2 (en) 2018-03-26 2021-01-12 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
EP4051665A1 (en) 2019-10-28 2022-09-07 Teva Pharmaceuticals International GmbH Solid state forms of arry-797 and process for preparation thereof
CN113354558B (zh) * 2021-07-12 2022-03-11 无锡双启科技有限公司 一种2-氨基-5-氟苯腈的制备方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5998060A (ja) * 1982-11-27 1984-06-06 Fujisawa Pharmaceut Co Ltd インダゾ−ル誘導体、その製造法および農薬
US4571255A (en) * 1983-12-29 1986-02-18 Ppg Industries, Inc. Subsituted phenoxybenzisoxazole herbicides
JPS6368568A (ja) * 1986-09-10 1988-03-28 Otsuka Pharmaceut Factory Inc ｐ−アミノフエノ−ル誘導体
NZ224714A (en) * 1987-06-01 1990-03-27 Janssen Pharmaceutica Nv Substituted benzotriazole derivatives and pharmaceutical compositions
IE910278A1 (en) * 1990-02-16 1991-08-28 Ici Plc Heterocyclic compounds
AU662997B2 (en) * 1992-07-03 1995-09-21 Ihara Chemical Industry Co. Ltd. Condensed heterocyclic derivative and weedkiller
AU682947B2 (en) * 1994-05-27 1997-10-23 Mochida Pharmaceutical Co., Ltd. Novel azolyl methyl phenyl derivatives having aromatase inhibitory activity
JP3382951B2 (ja) 1995-10-06 2003-03-04 メルク エンド カムパニー インコーポレーテッド 抗がん活性及びサイトカン阻害活性を有する置換イミダゾール
US5945418A (en) 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
EP1028954B1 (en) 1997-04-24 2003-07-02 Ortho-McNeil Pharmaceutical, Inc. Substituted imidazoles useful in the treatment of inflammatory diseases
US6087381A (en) 1997-05-22 2000-07-11 G. D. Searle & Company Pyrazole derivatives as p38 kinase inhibitors
US6093742A (en) 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
US6297239B1 (en) * 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
BR9812944A (pt) 1997-10-20 2000-08-08 Hoffmann La Roche Inibidores bicìclicos da cinase
JP2001521934A (ja) 1997-11-03 2001-11-13 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症薬としての芳香族ヘテロ環式化合物
GB9820767D0 (en) * 1998-09-23 1998-11-18 Cerebrus Ltd Chemical compounds VIII
EP1157026A1 (en) 1999-02-22 2001-11-28 Boehringer Ingelheim Pharmaceuticals Inc. Polycyclo heterocyclic derivatives as antiinflammatory agents
ES2251360T3 (es) 1999-03-12 2006-05-01 Boehringer Ingelheim Pharmaceuticals Inc. Compuestos heterociclicos aromaticos en calidad de agentes antiinflamatorios.
EE04799B1 (et) 1999-03-12 2007-04-16 Boehringer Ingelheim Pharmaceuticals, Inc. Ühendid, mis on kasulikud põletikuvastaste vahenditena, nende ühendite valmistamise meetodid ja neid sisaldavad farmatseutilised kompositsioonid
AU4063600A (en) * 1999-04-05 2000-10-23 Merck & Co., Inc. A method of treating cancer
HUP0201261A3 (en) 1999-05-21 2003-12-29 Scios Inc Sunnyvale Indole-type derivatives as inhibitors of p38 kinase and pharmaceutical compositions containing them
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
EP1235804A1 (en) * 1999-11-27 2002-09-04 Dong Wha Pharmaceutical Industrial Co. Ltd. Novel 3-nitropyridine derivatives and the pharmaceutical compositions containing said derivatives
AU4890301A (en) 2000-04-17 2001-10-30 Dong Wha Pharmaceutical Industrial Co., Ltd. 6-methylnicotinamide derivatives as antiviral agents
WO2002042292A2 (en) 2000-11-20 2002-05-30 Scios Inc. Indol derivative and their use as inhibitors of p38 kinase
US7102009B2 (en) * 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
AP2002002463A0 (en) 2001-03-09 2002-06-30 Pfizer Prod Inc Novel triazolo-pyrimides anti-inflammatory compounds.
EP1403255A4 (en) 2001-06-12 2005-04-06 Sumitomo Pharma INHIBITORS OF RHO KINASE
JP2005506350A (ja) 2001-10-18 2005-03-03 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン阻害薬としての１，４−二置換ベンゾ−縮合尿素化合物
AU2002353186A1 (en) * 2001-12-19 2003-06-30 Smithkline Beecham P.L.C. (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors
AU2003221184A1 (en) * 2002-03-29 2003-10-27 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for endothelial disorder
EP1562935B1 (de) * 2002-10-28 2006-09-06 Bayer HealthCare AG Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
AU2003293376A1 (en) * 2002-12-10 2004-06-30 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7129252B2 (en) * 2003-06-16 2006-10-31 Guoqing P Chen Six membered amino-amide derivatives an angiogenisis inhibitors
SE0301906D0 (sv) * 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
US20090048301A1 (en) * 2003-07-09 2009-02-19 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
CN1894240A (zh) * 2003-12-22 2007-01-10 伊莱利利公司 阿片受体拮抗剂
EP1883404A4 (en) * 2005-05-11 2010-03-31 Array Biopharma Inc P38 INHIBITORS AND METHODS OF USE

Also Published As

Publication number Publication date
US7521447B2 (en) 2009-04-21
JP4617299B2 (ja) 2011-01-19
WO2004078116A2 (en) 2004-09-16
RU2357957C2 (ru) 2009-06-10
CA2517517A1 (en) 2004-09-16
WO2004078116A9 (en) 2008-09-12
AU2004218463A1 (en) 2004-09-16
NO20054453D0 (no) 2005-09-26
AU2004218463B2 (en) 2009-07-16
WO2004078116A3 (en) 2004-10-14
NO20054453L (no) 2005-11-29
KR101099281B1 (ko) 2011-12-26
KR20050106484A (ko) 2005-11-09
NO328913B1 (no) 2010-06-14
RU2005131197A (ru) 2006-05-10
JP2006519259A (ja) 2006-08-24
IS2675B (is) 2010-09-15
US20040192653A1 (en) 2004-09-30
EP1606283B1 (en) 2008-10-08
EP1606283A2 (en) 2005-12-21
MXPA05009459A (es) 2006-05-17
PL214032B1 (pl) 2013-06-28
CA2517517C (en) 2012-12-18
IS8037A (is) 2005-09-21
EP1606283A4 (en) 2007-05-23

Similar Documents

Publication Publication Date Title
EG27049A (en) P38 inhibitors and methods of use thereof
PL378432A1 (pl) Inhibitory p38 i sposoby ich zastosowania
AU2003303128A8 (en) Inhibitors and methods of use thereof
HK1079789A1 (zh) 血管靜態毒性試劑及其使用方法
AU2003217870A8 (en) Pini-modulating compounds and methods of use thereof
AU2003213673A8 (en) Pin1-modulating compounds and methods of use thereof
IL173936A0 (en) Heterocyclic inhibitors of mek and methods of use thereof
EP1606285A4 (en) IDO INHIBITORS AND METHODS OF USE THEREOF
EP1507756A4 (en) CCR9 INHIBITORS AND USE THEREOF
EP1465615A4 (en) TRICYCLIC BISENONE DERIVATIVES AND METHODS OF USE
IL213843A0 (en) 4-aminotetracyclines and methods of use thereof
IL174431A0 (en) Substituted benzazoles and use thereof as inhibitors of raf kinase
AU2003259735A8 (en) Small-mer compositions and methods of use
EP1691812A4 (en) GTPASE INHIBITORS AND METHOD OF USE
EP1448218A4 (en) BETA SECRETASE INHIBITORS AND METHODS OF USE
ZA200601293B (en) Proteasome inhibitors and methods of using the same
EP1789437A4 (en) INHIBITORS OF NPC1L1 AND NPC1L1 AND METHODS OF USE THEREOF
EP1476150A4 (en) CARBOXY FULLERES AND USE METHOD THEREFOR
AU2003299441A8 (en) Nf-hev compositions and methods of use
EP1663255A4 (en) WITHANAMID AND WITHANOLID COMPOSITIONS AND APPLICATION METHOD THEREFOR
EP1633749A4 (en) DEAZAFLAVIN COMPOUNDS AND METHODS OF USE
EP1883404A4 (en) P38 INHIBITORS AND METHODS OF USE
AU2003210983A8 (en) Kinase inhibitors and methods of use thereof
EP1682115A4 (en) HIF-1 HEMMER AND APPLICATION METHOD THEREFOR
EP1625141A4 (en) GRP94-BASED COMPOSITIONS AND METHODS OF USE THEREOF